The bankrupt gene editing biotech Sangamo is set to sell chunks of its business to PTC Therapeutics and Eli Lilly for up to $264 million following an auction procedure.
August 13, 2026 06:30 AM EDT
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction
The bankrupt gene editing biotech Sangamo is set to sell chunks of its business to PTC Therapeutics and Eli Lilly for up to $264 million …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Sangamo Therapeutics files for bankruptcy after three decades, selling assets to Eli Lilly for $50M and Astellas for up to $50M,…
Sangamo files for Chapter 11 as Eli Lilly and Astellas step in to buy its valuable gene therapy and genome-editing assets.
Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230…
Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and…
Curium acquires Lantheus for $102.5/share (~$8B); Sandoz settles price-fixing for $478.5M; Latigo eyes $247M IPO for non-opioid…
PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4…
